Evidence map›Paper›PMID 33263285›Full record

ArticleExperimental eye research2021

TGFβ1 and TGFβ2 proteins in corneas with and without stromal fibrosis: Delayed regeneration of apical epithelial growth factor barrier and the epithelial basement membrane in corneas with stromal fibrosis.

Rodrigo Carlos de Oliveira, George Tye, Lycia Pedral Sampaio, Thomas Michael Shiju, JodiRae DeDreu, A Sue Menko, Marcony R Santhiago, Steven E Wilson

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Experimental eye research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07449000 (Topical Losartan as Treatment to Reduce Corneal Scarring Fibrosis), which is not on this map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07449000 narecruitingnot on this mapstarted 2026, after this paper: background citation

Topical Losartan as Treatment to Reduce Corneal Scarring Fibrosis

TypeinterventionalSponsorUniversidad Autonoma de Nuevo LeonRan2026 to 2027Enrolled46ConditionsCorneal Scarring FibrosisArmsTopical losartan, Placebo Control
3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Topical Losartan: Practical Guidance for Clinical Trials in the Prevention and Treatment of Corneal Scarring Fibrosis and Other Eye Diseases and Disorders.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2023
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Rodrigo Carlos de OliveiraThe Cole Eye Institute, The Cleveland Clinic, Cleveland, OH, USA.
George TyeThe Cole Eye Institute, The Cleveland Clinic, Cleveland, OH, USA.
Lycia Pedral SampaioThe Cole Eye Institute, The Cleveland Clinic, Cleveland, OH, USA.
Thomas Michael ShijuThe Cole Eye Institute, The Cleveland Clinic, Cleveland, OH, USA.
JodiRae DeDreuDepartment of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA, USA.
A Sue MenkoDepartment of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA, USA.
Marcony R SanthiagoDepartment of Ophthalmology, University of São Paulo, Sao Paulo, Brazil and, University of Southern California Roski Eye Institute, Los Angeles, CA, USA.
Steven E WilsonThe Cole Eye Institute, The Cleveland Clinic, Cleveland, OH, USA. Electronic address: wilsons4@ccf.org.
Cleveland Clinic · USThomas Jefferson University · USUniversity of Southern California · US

Funding

RESOURCE/SERVICE CORE C - MOLECULAR INFORMATICS MODULEP30EY025585 · NEI · CLEVELAND CLINIC LERNER COM-CWRU · PI Brian D Perkins · 2016 to 2026
$7.7M
Corneal Epithelial Growth Factors and ReceptorsR01EY010056 · NEI · UNIVERSITY OF WASHINGTON · PI WILSON, STEVEN EUGENE · 1994 to 2020
$7.4M
Paradigms of Wound Healing and Fibrosis in the EyeR01EY021784 · NEI · THOMAS JEFFERSON UNIVERSITY · PI A. Sue Menko, Mary Ann Stepp · 2011 to 2026
$7.3M
Cole Eye Institute Vision Science Training ProgramT32EY024236 · NEI · CLEVELAND CLINIC LERNER COM-CWRU · PI ANAND-APTE, BELA · 2015 to 2025
$1.0M
Leica TCS SP8 Confocal Microscope for a Core FacilityS10OD019972 · OD · CLEVELAND CLINIC LERNER COM-CWRU · PI DRAZBA, JUDY · 2015 to 2015
$544k
NEI NIH HHS P30 EY025585NEI NIH HHS R01 EY010056NEI NIH HHS R01 EY021784NEI NIH HHS T32 EY024236NIH HHS S10 OD019972
6 · The paper itself

Abstract

The purpose of this study was to investigate the expression and localization of transforming growth factor (TGF) β1 and TGFβ2 in rabbit corneas that healed with and without stromal fibrosis, and to further study defective perlecan incorporation in the epithelial basement membrane (EBM) in corneas with scarring fibrosis. A total of 120 female rabbits had no surgery, -4.5D PRK, or -9D PRK. Immunohistochemistry (IHC) was performed at time points from unwounded to eight weeks after surgery, with four corneas at each time point in each group. Multiplex IHC was performed for TGFβ1 or TGFβ2, with Image-J quantitation, and keratocan, vimentin, alpha-smooth muscle actin (SMA), perlecan, laminin-alpha 5, nidogen-1 or CD11b. Corneas at the four-week peak for myofibroblast and fibrosis development were evaluated using Imaris 3D analysis. Delayed regeneration of both an apical epithelial growth factor barrier and EBM barrier function, including defective EBM perlecan incorporation, was greater in high injury -9D PRK corneas compared to -4.5D PRK corneas without fibrosis. Defective apical epithelial growth factor barrier and EBM allowed epithelial and tear TGFβ1 and tear TGFβ2 to enter the corneal stroma to drive myofibroblast generation in the anterior stroma from vimentin-positive corneal fibroblasts, and likely fibrocytes. Vimentin-positive cells and unidentified vimentin-negative, CD11b-negative cells also produce TGFβ1 and/or TGFβ2 in the stroma in some corneas. TGFβ1 and TGFβ2 were at higher levels in the anterior stroma in the weeks preceding myofibroblast development in the -9D group. All -9D corneas (beginning two to three weeks after surgery), and four -4.5D PRK corneas developed significant SMA + myofibroblasts and stromal fibrosis. Both the apical epithelial growth factor barrier and/or EBM barrier functions tended to regenerate weeks earlier in -4.5D PRK corneas without fibrosis, compared to -4.5D or -9D PRK corneas with fibrosis. SMA-positive myofibroblasts were markedly reduced in most corneas by eight weeks after surgery. The apical epithelial growth factor barrier and EBM barrier limit TGFβ1 and TGFβ2 entry into the corneal stroma to modulate corneal fibroblast and myofibroblast development associated with scarring stromal fibrosis. Delayed regeneration of these barriers in corneas with more severe injuries promotes myofibroblast development, prolongs myofibroblast viability and triggers stromal scarring fibrosis.

Indexed as

AnimalsBasement MembraneCorneaCorneal OpacityCorneal StromaEpithelium, CornealFemaleFibrosisMembrane ProteinsMicroscopy, ConfocalRabbitsRegenerationTransforming Growth Factor beta1Transforming Growth Factor beta2Membrane ProteinsTransforming Growth Factor beta1Transforming Growth Factor beta2Corneal fibroblastsCorneal scarringEpithelial barrier functionEpithelial basement membraneFibrocytesFibrosisMacrophagesMonocytesMyofibroblastsPerlecanSecretory vesiclesTransforming growth factor beta-1Transforming growth factor beta-2

Identifiers

PMID33263285
PMCPMC7856119
OpenAlexW3094298153

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.